← Leaderboards
Jeffrey H Newcorn
Mount Sinai School Of Medicine Of Nyu
$5,863,865
Attributed
$7,905,257
Total exposure
8
Grants
7
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $714.2K · FY2005–20$1M$750K$500K$250K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
Funding mix
By agency
NIH$7,905,257 · 8
By mechanism
R01$6,160,057 · 2
R21$1,671,310 · 3
M01$73,890 · 3
Top collaborators
- Kurt P. Schulz5 shared
- Iliyan Stoyanov Ivanov4 shared
Most similar at Mount Sinai School Of Medicine Of Nyu
Same institution · by research overlap
- Kurt P. Schulz$3,189,700
- Joel Erblich$4,800,720
- Kenneth L Davis$4,485,046
Others in their field
Top investigators on “Response”
- Lawrence Corey · Fred Hutchinson Cancer Center$677,505,141
- David Divins · Consortium For Ocean Leadership, Inc$609,772,544
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$532,027,174
- Barton F Haynes · Duke University$497,761,007
- Jeffrey P Krischer · University Of South Florida$397,532,270
- Glenda E Gray · Wits Health Consortium (Pty), Ltd$342,310,423
Research focus
ResponseAttention Deficit Hyperactivity DisorderYouthNeurobiologyChildAtomoxetineMethylphenidateAdolescentReportingTreatment EffectFunctional Magnetic Resonance ImagingBrainInnovationAftercareCharacteristicsDoseNeuroimagingPharmaceutical PreparationsBaseSafetyFunctional DisabilityFundingUnited States National Institutes Of HealthComorbidity
Grant awards (21)
Brain Indices of Stimulant Treatment in Drug-Naive Youth at Risk for Substance Use Disorder$211,875
R21 · FY2020 · DA · contact PI
Brain Indices of Stimulant Treatment in Drug-Naive Youth at Risk for Substance Use Disorder$254,250
R21 · FY2019 · DA · contact PI
Stimulant vs. non-stimulant treatments and reward processing in drug-naive youth at SUD risk$211,875
R21 · FY2019 · DA · contact PI
Stimulant vs. non-stimulant treatments and reward processing in drug-naive youth at SUD risk$254,250
R21 · FY2018 · DA · contact PI
Imaging Stimulant and NonStimulant Treatments for ADHD: A Network-Based Approach$540,613
R01 · FY2016 · MH · contact PI
Imaging Stimulant and NonStimulant Treatments for ADHD: A Network-Based Approach$640,459
R01 · FY2015 · MH · contact PI
Imaging Stimulant and NonStimulant Treatments for ADHD: A Network-Based Approach$640,461
R01 · FY2014 · MH · contact PI
Imaging Stimulant and NonStimulant Treatments for ADHD: A Network-Based Approach$614,841
R01 · FY2013 · MH · contact PI
Imaging Stimulant and NonStimulant Treatments for ADHD: A Network-Based Approach$714,161
R01 · FY2012 · MH · contact PI
Predicting Response to Atomoxetine and Methlyphenidate$597,413
R01 · FY2009 · MH · contact PI
MEASURING AND PREDICTING RESPONSE TO ATOMOXETINE AND METHYLYPHENIDATE$18,840
M01 · FY2009 · RR · contact PI
Predicting Response to Atomoxetine and Methlyphenidate$648,558
R01 · FY2008 · MH · contact PI
MEASURING AND PREDICTING RESPONSE TO ATOMOXETINE AND METHYLYPHENIDATE$50,796
M01 · FY2008 · RR · contact PI
Predicting Response to Atomoxetine and Methlyphenidate$656,585
R01 · FY2007 · MH · contact PI
MEASURING AND PREDICTING RESPONSE TO ATOMOXETINE AND METHYLYPHENIDATE$4,254
M01 · FY2007 · RR · contact PI
Predicting Response to Atomoxetine and Methlyphenidate$451,280
R01 · FY2006 · MH · contact PI
Methylphenidate and Atomoxetine in ADHD: fMRI Measures of Mechanisms and Response$202,116
R01 · FY2006 · MH · contact PI
Predicting Response to Atomoxetine and Methlyphenidate$453,570
R01 · FY2005 · MH
Dopamine and ADHD: A Research Infrastructure Network$234,770
R21 · FY2004 · MH
Dopamine and ADHD: A Research Infrastructure Network$234,770
R21 · FY2003 · MH
Dopamine and ADHD: A Research Infrastructure Network$269,520
R21 · FY2002 · MH